Kallyope, Inc. logo

Kallyope, Inc.

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gut-brain axis, which offers opportunities to access and influence brain centers involved in fundamental human processes.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.kallyope.com
Disease Focus
STOCK CODENon Listed
Address
430 East 29th Street, 10th Floor, NY 10016
New York
United States
Email
Contact Number

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gut-brain axis, which offers opportunities to access and influence brain centers involved in fundamental human processes.

The companys founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D. and Nobel laureate Richard Axel, M.D. Headquartered at the Alexandria Centerë for Life Science in New York City.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/kallyope” connections=”true” suffix=””]

In Feb 2018, Kallyope Inc received $66 million Series B financing investors participated in the Series B, including Lux Capital, The Column Group, Polaris Partners, Illumina Ventures, and Alexandria Venture Investments. New investors Euclidean Capital and Two Sigma Ventures also joined the syndicate.

In Dec 2015, Kallyope raised $44 Mn in Series A financing round. Key investors includes Lux Capital, Polaris Partners, Alexandria Venture Investments, The Column Group and Illumina.